This report provides all the information you require to better understand Eli Lilly and its partnering interests and activities over the past seven years.

Eli Lilly is a top pharmaceutical company based in Indianapolis, Indiana, USA

Eli Lilly, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Eli Lilly has announced over 8 M&A deals since 2005, with the lead deals being the acquisition of Imclone Systems and Icos

Eli Lilly announced over 150 partnering / licensing deals since 2005, with over 14 deals in 2012 alone

Eli Lilly is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and animal health

Partnering continues to be buoyant in the run up to BIO2012 in Boston

Eli Lilly won’t be making any mega pharmaceutical deals, Chairman and Chief Executive John Lechleiter said

Eli Lilly, a big pharma company facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting to overcome the revenue loss, Chief Executive Officer John Lechleiter said

The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value

Indian pharmaceutical company, Zydus Cadila is planning to withdraw from its collaboration with Eli Lilly that involved joint drug discovery for cardiovascular diseases. 

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate (“TT701”) from Eli Lilly and Company.

Eli Lilly and Hanmi Pharmaceutical have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi’s oral Bruton’s tyrosine kinase (BTK) inhibitor, HM71224

Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company

Bristol-Myers Squibb and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib

Merck and Eli Lilly announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials

Eli, Lilly and Company pharma partners on a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease.

Eli Lilly and Adocia announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro

Eli Lilly and Company, Anthem, Inc. and HealthCore pharma partners for a five-year, real-world evidence research collaboration intended to improve health outcomes for patients.

Zosano Pharma and Eli Lilly have entered into an exclusive agreement to develop ZP-PTH

Denovo Biopharma has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company.